A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Clinical trial NCT05673928 · RECRUITING
Trial details
- NCT number
- NCT05673928
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-16
- Primary completion
- 2027-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.